Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

9.44
+0.61006.91%
Post-market: 9.520.0800+0.85%19:59 EDT
Volume:27.29M
Turnover:263.21M
Market Cap:10.00B
PE:-9.55
High:10.09
Open:8.92
Low:8.90
Close:8.83
52wk High:12.43
52wk Low:1.95
Shares:1.06B
Float Shares:407.00M
Volume Ratio:2.87
T/O Rate:6.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9887
EPS(LYR):-0.3820
ROE:78.05%
ROA:-30.54%
PB:-9.56
PE(LYR):-24.71

Loading ...

Immunitybio Inc Stock (IBRX) Moved Up by 11.15% on Sep 30: What Signal Does It Send?

TradingKey
·
6 hours ago

ImmunityBio rises 12.3%

TIPRANKS
·
8 hours ago

ImmunityBio’s New Sepsis Trial: Early-Stage Data With High-Stakes Market Potential

TIPRANKS
·
Sep 26

ImmunityBio call volume above normal and directionally bullish

TIPRANKS
·
Sep 23

PDS Biotech Adds Patrick Soon-Shiong, NantBio CFO James Banaag to Board

Reuters
·
Sep 14

PDS Biotech Announces Initial Closing of up to $22.3 Million Pipe Financing and the Appointment of DR. Patrick Soon-Shiong to Its Board of Directors

THOMSON REUTERS
·
Sep 14

ImmunityBio put volume heavy and directionally bearish

TIPRANKS
·
Sep 10

Does ImmunityBio’s (IBRX) Jim Yong Kim Hire Transform Its Global Access Strategy For Immunotherapies?

Simply Wall St.
·
Aug 25

Does Adding Jim Yong Kim to Leadership Shift ImmunityBio’s Global Strategy Narrative (IBRX)?

Simply Wall St.
·
Aug 15

ImmunityBio Names Former World Bank Chief Jim Yong Kim Vice Chairman

Reuters
·
Aug 10

Immunitybio Appoints DR. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

THOMSON REUTERS
·
Aug 10

Why ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next

Simply Wall St.
·
Aug 08

Travere Therapeutics Q2 Product Sales Rise on Filspari Demand

Reuters
·
Aug 05

U.S. Stocks on the MOVE-Expeditors International, Waters, Wayfair

Reuters
·
Aug 05

Immunitybio Falls After Posting Q2 Loss

Reuters
·
Aug 04

Shares of Immunitybio Down 3.5% Premarket After Posting Q2 Loss

THOMSON REUTERS
·
Aug 04

Immunitybio Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 04

Earnings Flash (IBRX) ImmunityBio Posts Q2 Net Loss $0.22 a Share, vs. FactSet Est of $0.08 Loss

MT Newswires Live
·
Aug 04

ImmunityBio Q2 Adj. EPS $(0.08) Beats $(0.09) Estimate, Sales $51.240M Beat $49.700M Estimate

Benzinga Earnings
·
Aug 04

ImmunityBio Q2 FY26 Net Loss Widens to $230.4 Million; Revenue Rises 92% YoY to $50.7 Million

Reuters
·
Aug 04